MIRM: Mirum Pharma Company Value to Net Income

Symbol and logo of brand Mirum Pharmaceuticals, Inc. (MIRM)

Mirum Pharmaceuticals (MIRM) management has solidified its dominance in the treatment of pediatric cholestatic pathologies through patents. The business's P/E ratio visualizes this success, with the current level standing at -6.90. Growth is accelerating through the implementation of AI platforms for rare disease analysis, while the expansion strategy into new indications aims for the complete monopolization of the liver therapy niche.

MIRM - Mirum P/E Multiple over the range 07/04/2022 - 11/15/2026

Comprehensive metric breakdowns and analytics for Mirum Pharmaceuticals, Inc. (MIRM)

- price and consensus price forecast:
Stock Price Mirum Pharma|MIRM - Consensus Target
- market capitalization information:
Market Value Mirum Pharma|MIRM - Total Company Value
- balance sheet net asset value indicators:
Net Assets per Single Share Mirum Pharmaceuticals|MIRM - Book Capitalization|Market Capitalization to Book Value mirumpharma.com|MIRM - Cumulative Company Assets
- company liabilities and liquidity data:
Debt to Equity Mirum Pharmaceuticals|MIRM - Long-Term Debt to Capital|Current Liabilities to Capital mirumpharma.com|MIRM - Company Debts|Debt to Net Assets Ratio Mirum Pharma|MIRM - Company Long-Term Debt|Company Current Liabilities Mirum Pharmaceuticals|Interim Coverage Ratio mirumpharma.com
- earnings and market ratios statistics:
MIRM - Company Net Income|Expected Net Income Mirum Pharmaceuticals|MIRM - Price to Earnings Ratio|Forward P/E Multiple Mirum Pharmaceuticals Inc|MIRM - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Mirum Pharmaceuticals Inc|MIRM - Operating profit before deduction of amortization|Earnings per share for the trailing year Mirum Pharmaceuticals|MIRM - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months mirumpharma.com|MIRM - Earnings growth in current year|Expected earnings per share trend next year Mirum Pharmaceuticals
- company sales and revenue statistics:
MIRM - Revenue and Sales Volume|Projected Sales Volume Mirum Pharmaceuticals, Inc.|MIRM - Price-to-Revenue Ratio|Forward Price to Sales Mirum Pharma|MIRM - Sales Growth YoY (Last Twelve Months)
Comprehensive company analysis:Mirum Pharmaceuticals, Inc. - MIRM
Brand item of Mirum

Market expectations for Mirum Pharmaceuticals (MIRM) depend on the ratio of market capitalization to net income, which allows for an assessment of the cost per unit of earnings. By analyzing the company's fundamental P/E, an investor can see how scaling sales of orphan drugs offsets fixed R&D costs, transforming the biotech asset into a commercially efficient business with growing operating margins.

Analysis of competing companies

P/E Multiple Arrowhead Pharmaceuticals Inc|Price to Earnings Ratio DVAX (Dynavax Technologies)|ABUS (Tekmira Pharmaceuticals) - Company Value to Net Income|P/E Multiple IVA (inventivapharma.com)|Gyre Therapeutics, Inc. - Price to Earnings Ratio|Assembly Bio - P/E Multiple|Business Payback Period Galectin Therapeutics, Inc. GALT|GNFT (Genfit SA) - Price to Earnings Ratio|DRRX (DURECT Corp) - Price to Earnings Ratio|ALGS (Aligos Therapeutics Inc.) - P/E Multiple|Market Cap to Earnings biovieinc.com BIVI|Price to Earnings Ratio Galmed Pharmaceuticals Ltd (GLMD)|NDRA (ENDRA Life Sciences Inc.) - Company Value to Net Income|P/E Multiple HEPA (Hepion Pharmaceuticals)